Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$0.38.

  • Coherus Oncology's EPS (Basic) rose 731.71% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 57638.89%. This contributed to the annual value of $0.25 for FY2024, which is 10988.14% up from last year.
  • Latest data reveals that Coherus Oncology reported EPS (Basic) of -$0.38 as of Q3 2025, which was up 731.71% from $2.57 recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EPS (Basic) ranged from a high of $2.57 in Q2 2025 and a low of -$2.37 during Q1 2021
  • Over the past 5 years, Coherus Oncology's median EPS (Basic) value was -$0.49 (recorded in 2021), while the average stood at -$0.32.
  • As far as peak fluctuations go, Coherus Oncology's EPS (Basic) plummeted by 57400.0% in 2021, and later skyrocketed by 63541.67% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's EPS (Basic) stood at -$0.61 in 2021, then fell by 25.41% to -$0.76 in 2022, then rose by 2.63% to -$0.74 in 2023, then soared by 333.78% to $1.73 in 2024, then plummeted by 121.97% to -$0.38 in 2025.
  • Its last three reported values are -$0.38 in Q3 2025, $2.57 for Q2 2025, and -$0.49 during Q1 2025.